MARKET

CRBP

CRBP

Corbus Pharmaceu
NASDAQ
11.35
-0.16
-1.39%
After Hours: 11.49 +0.14 +1.23% 18:41 05/22 EDT
OPEN
11.46
PREV CLOSE
11.51
HIGH
12.88
LOW
11.26
VOLUME
556.44K
TURNOVER
--
52 WEEK HIGH
20.56
52 WEEK LOW
6.72
MARKET CAP
210.29M
P/E (TTM)
-1.9529
1D
5D
1M
3M
1Y
5Y
1D
Corbus Pharma Chief Business Officer Nishant Saxena files initial beneficial ownership statement
PUBT · 1d ago
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho
Dow Jones · 1d ago
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44
Benzinga · 1d ago
Corbus Pharmaceuticals (CRBP) Gets a Buy from RBC Capital
TipRanks · 1d ago
Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
TipRanks · 1d ago
Analysts Conflicted on These Healthcare Names: Zoetis (ZTS), Cencora (COR) and Corbus Pharmaceuticals (CRBP)
TipRanks · 2d ago
CORBUS PHARMACEUTICALS HOLDINGS INC <CRBP.O>: MIZUHO RAISES TARGET PRICE TO $44 FROM $40
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday
Reuters · 2d ago
More
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Webull offers Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ: CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.